NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

EP: 1.Exploring the Landscape Surrounding Light Chain Amyloidosis

EP: 2.Expert Perspectives on Differentiating Signs and Symptoms in AL Amyloidosis Diagnosis

EP: 3.Exploring Diagnostic Approaches for Patients with Light Chain Amyloidosis

EP: 4.Current Treatment Landscape for AL Amyloidosis

EP: 5.Unmet Needs and Treatment Considerations in Managing AL Amyloidosis

EP: 6.Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis

EP: 7.Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs

EP: 8.Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement

EP: 9.The Role of Cardiac Staging in Patients with AL Amyloidosis

EP: 10.Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

EP: 11.AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

EP: 12.Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

EP: 13.The Potential Role of CAR T Therapy in AL Amyloidosis

Now Viewing

EP: 14.NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

EP: 15.Looking Ahead: Future Perspectives on AL Amyloidosis

This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.

A presentation at the American Society of Hematology meeting revealed promising data on B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy (NXC-201) for light chain (AL) amyloidosis. In a study involving 9 patients with a median of 6 prior lines of therapy, BCMA-directed CAR T cell achieved a 100% hematologic response rate, with 6 patients achieving complete hematologic responses. The median time to hematologic response was less than a month, and cytokine release syndrome was generally mild (grades 1 and 2). However, despite these positive outcomes, 6 patients died at a median follow-up of 7 months, with 1 death attributed to COVID-19 pneumonia.

The CAR T-cell therapy showed great efficacy with a favorable safety profile, demonstrating potential for AL amyloidosis treatment. Although challenges exist, including concerns about cardiac progression and immune fitness in patients with extensive prior therapy, the therapy’s impact on patients with amyloidosis not requiring ongoing treatment raises optimism. The results suggest a potential 1-shot solution for achieving durable hematologic responses and possibly improving organ responses, ushering in a new era in AL amyloidosis management.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.